Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum - Infected mosquitoes: An update

Journal of Infectious Diseases

Volumn 196, Issue 1, 2007, Pages 145-154

  Epstein, Judith E ^a   Rao, Suchitra ^a,c   Williams, Frank ^a   Freilich, Daniel ^a   Luke, Thomas ^a,d   Sedegah, Martha ^a   De La Vega, Patricia ^a   Sacci, John ^a,e   Richie, Thomas L ^a   Hoffman, Stephen L ^a,b  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b SANARIA INC   (United States)

^c CHILDREN S HOSPITAL   (United States)

^d Bureau of Medicine and Surgery   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE;

ADULT; ANOPHELES; BLOOD SMEAR; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; INCUBATION TIME; LABORATORY TEST; MALARIA; MALE; MEDICAL RECORD REVIEW; MOSQUITO; NORMAL HUMAN; OUTCOME ASSESSMENT; PARASITE ISOLATION; PARASITEMIA; PARASITOSIS; PHYSICAL EXAMINATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROVOCATION TEST; REPRODUCIBILITY; REVIEW; SAFETY; SPOROZOITE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANIMALS; CULICIDAE; FEMALE; HUMAN EXPERIMENTATION; HUMANS; INSECT BITES AND STINGS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; SAFETY; TIME FACTORS;

EID: 34250827428     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518510     Document Type: Review

References (40)

1. Breman JG, Egan A, Keusch GT. The intolerable burden of malaria: a new look at the numbers. Am J Trop Med Hyg 2001; 64(1-2 Suppl):iv-vii.
2. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973; 266:169-77.
3. Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 1973; 266:398-401.
4. Clyde DF, McCarthy VC, Miller RM, Woodward WE. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975; 24:397-401.
5. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1974; 68:258-9.
6. Rieckmann KH, Beaudoin RL, Cassells JS, Sell DW. Use of attenuated sporozoite in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 1979; 57:261-5.
7. James SP, Shute PG. Malaria Commission: report on the first results of laboratory work on malaria in England. C.H./Malaria/57. Geneva: League of Nations Health Organization, 1926.
8. Nicol WD. The care and management of induced malaria. J Ment Sci 1927; April:1-9.
9. James SP. Some general results of a study of induced malaria in England. Trans R Soc Trop Med Hyg 1931; 24:477-538.
10. Covell G, Nicol WD. Clinical, chemotherapeutic and immunologic studies on induced malaria. Br Med Bull 1951; 8:51-5.
11. Hall WS. General paresis, the South Carolina Hospital and the U.S. Public Health Service Laboratory associated therewith. Rec Columbia Med Soc Richland County 1955; 19:7-14, 23-9.
12. Chulay JD, Schneider I, Cosgriff TM, et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986; 35:66-8.
13. Church LWP, Le PL, Bryan JP, et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 1997; 175:915-20.
14. Hoffman S. Experimental challenge of volunteers with malaria. Ann Int Med 1997; 127:233-5.
15. Wang R, Richie TL, Baraceros MF, et al. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun 2005; 73:2863-72.
16. Heppner DG, Gordon DM, Gross M, et al. Safety, immunogenicity and efficacy of Plasmodium repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis 1996; 174:361-6.
17. Stoute JA, Slaoui M, Heppner G, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997; 336:86-90.
18. Stoute JA, Kester KE, Krzych BT, et al. Long-term efficacy and immune responses following immunization with the RTS,S vaccine. J Infect Dis 1998; 178:1139-44.
19. Ockenhouse CF, Sun PF, Lanar DE, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998; 177:1664-73.
20. Kester KE, McKinney DA, Tornieporth N, et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001; 183:640-7.
21. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185:1155-64.
22. Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005; 102:4836-41.
23. McConkey SJ, Reece WHH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9:729-35.
24. Hermsen CC, Konijnenberg Y, Mulder L, et al. Circulating concentrations of soluble granzyme A and B increase during natural and experimental Plasmodium falciparum infections. Clin Exp Immunol 2003; 132:467-72.
25. Hermsen CC, De Vlas SJ, Jan G, et al. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg 2004; 71:196-201.
26. Lavstsen T, Magistrado P, Hermsen C, et al. Expression of Plasmodium falciparum erythrocyte membrane protein I in experimentally infected humans. Malar J 2005; 4:21.
27. Walther M, Dunachie S, Keating S, et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 2005; 23:857-64.
28. Verhage DF, Telgt DSC, Bousema JT, et al. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med 2005; 63:52-8.
29. Dunachie S, Walther M, Vuola J, et al. A clinical trial of prime-boost immunization with the candidate malaria vaccines RTS,S/ASO2A and MVA-CS. Vaccine 2006; 24:2850-9.
30. Walther M, Thompson FM, Dunachie S, et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus encoding the full-length Plasmodium falciparum circumsporozoite gene. Infect Immun 2006; 74:2701-16.
31. Dunachie SJ, Walther M, Epstein JE, et al. A DNA prime-MVA boost vaccine encoding TRAP but not circumsporozoite protein protects healthy malaria-naive adults against P. falciparum sporozoite challenge. Infect Immun 2006; 74:5933-42.
32. McCall MB, Beynon AJ, Mylanus EA, van der Ven AJ, Sauerwein RW. No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria. Trans R Soc Trop Med Hyg 2006; 100:1098-104.
33. Warrell DA, Molyneux ME, Beales PF. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990; 84(Suppl 2):1-65.
34. World Health Organization (WHO). Guidelines for the treatment of malaria. Geneva: WHO, 2006.
35. Hoffman SL, Campbell CC, White NJ. Malaria. In: Guerrant R, Walker D, Weller P, eds. Tropical infectious diseases: principles, pathogens, and practice. 2nd ed. Philadelphia: Elsevier, 2006:1024-59.
36. Ladhani S, Lowe B, Cole AO, Kowuondo K, Newton CR. Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome. Br J Haematol 2002; 119:839-47.
37. McKenzie FE, Prudhomme WA, Magill AJ, et al. White blood cell counts and malaria. J Infect Dis 2005; 192:323-30.
38. Kemp K, Akanmori BD, Kurtzhals JA, et al. Acute P. falciparum malaria induces a loss of CD28-T IFN-γ producing cells. Parasite Immunol 2002; 24:545-8.
39. Wipasa J, Xu H, Stowers A, et al. Apoptotic deletion of Th cells specific for the 19-kDa carboxyl-terminal fragment of merozoite surface protein 1 during malaria infection. J Immunol 2001; 167:3903-9.
40. Ghoda MK. Falciparum hepatopathy: a reversible and transient involvement of liver in falciparum malaria. Trop Gastroenterol 2002; 23:70-1.